Threshold of dopamine content and D1 receptor stimulation necessary for the expression of rotational behavior induced by D2 receptor stimulation under normo and supersensitive conditions

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 355, Issue 1, 1996, Pages 30-35

  Dziewczapolski, Gustavo ^a   Mora, Marcelo A ^a   Menalled, Liliana B ^a   Stéfano, Francisco J E ^a   Rubinstein, Marcelo ^b   Gershanik, Oscar S ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

Author keywords

Circling behavior; Dopamine agonists; Dopamine receptors; Endogenous dopamine; Rat

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; DESIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; METIROSINE; PERGOLIDE MESILATE; QUINOLINIC ACID; QUINPIROLE;

ANIMAL EXPERIMENT; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031023260     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004914     Document Type: Article

References (45)

1. Agid Y, Javoy F, Glowinski J (1973) Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature 245:150-151
2. 2 receptor sites in reserpine-pretreated but not in normal rats. Eur J Pharmacol 113:79-88
3. 2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6- hydroxydopamine lesions. Eur J Pharmacol 102:349-354
4. 2 receptors in the circling behavior induced by apomorphine, SK and F 38393, pergolide and LY 171555 in 6-OHDA lesioned rats. Psychopharmacology 85:346-352
5. 2 dopamine receptor interactions. Eur J Pharmacol 123:109-114
6. 1 stimulation in normal and MPTP monkeys. Neurosci Lett 104:223-228
7. 2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. Adv Neurol 60:113-118
8. 2 dopamine receptor agonists on levodopa-induced dyskinesia in MPTP monkeys. J Pharmacol Exp Ther 267:275-279
9. 1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 68:41-50
10. 2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study. Brain Res 400:205-218
11. Carman LS, Gage FH, Shults CW (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res 553:275-283
12. 2 dopamine receptor classification and its functional implications. Synapse 1:347-388
13. Close SP, Marriott AS, Pay S (1985) Failure of SKF 38393-A to relieve parkinsonian symptoms induced by MPTP in the marmoset. Br J Pharmacol 85:320-322
14. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Les AJ (1996) Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 61:634-637
15. 2 receptors in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 265:1387-1391
16. Dravid A, Jaton AL, Enz A, Frei P (1984) Spontaneous recovery from motor asymmetry in adult rats with 6-hydroxydopamine-induced partial lesions of the substantia nigra. Brain Res 311:361-365
17. Gershanik O, Heikkila RE, Duvoisin RC (1983) Effects of dopamine depletion on rotational behavior to dopamine agonists. Brain Res 261:358-360
18. Goldstein M, Lieberman A, Meller E (1985) A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. Trends Pharmacol Sci 6:436-437
19. Goldstein M, Lieberman A, Meller E (1986) Goldstein et al. reply (letter). Trends Pharmacol Sci 7:225-228
20. 2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine trated monkeys. J Pharmacol Exp Ther 259:409-413
21. Hefti F, Melamed E, Wurtman RJ (1980) Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 195:123-137
22. 1 receptors. J Neural Transm 69:131-145
23. 1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229:203-209
24. König JFR, Klippel RA (1963) The rat brain. A stereotaxic atlas of the forebrain and lower parts of the brain stem. Williams & Wilkins, New York
25. 1 receptor activation. Mov Disorders 5:78
26. 2 receptors in "MPTP" monkeys. Eur J Pharmacol 253:215-224
27. 1 agonist SKF 38393. Neuropharmacology 25:947-949
28. 1 agonist SKF 38393 reverses parkinsonism induced by 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci Lett 57:37-4
29. 2 dopamine agonists on turning behaviour in rats. Brain Res 384:387-390
30. Robertson HA, Robertson GS (1986) The antiparkinson action of bromocriptine in combination with levodopa (letter). Trends Pharmacol Sci 7:224-227
31. Robertson HA, Robertson GS (1987) Combined L-Dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action. Clin Neuropharmacol 10:384-387
32. Schwarcz R, Fuxe K, Agnati LF, Hökfelt T, Coyle JT (1979) Rotational behaviour in rats with unilateral striatal kainic acid lesions: a behavioural model for studies on intact dopamine receptors. Brain Res 170:485-495
33. Schwartz JC, Giros B, Martres MP, Sokoloff P (1992) The dopamine receptor family: molecular biology and pharmacology. Semin Neurosci 4:99-108.
34. 1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. J Pharmacol Exp Ther 276:150-160
35. 2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. J Pharmacol Exp Ther 247:180-185
36. 1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 199:389-391
37. 1 dopamine receptor partial agonist CY-208243 exhibit antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol 156:197
38. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-OHDA lesions of the nigrostriatal dopamine system. Brain Res 24:485-493
39. 1 dopaminergic tone (letter). Trends Pharmacol Sci 7:223-224
40. 1 dopamine receptor and the search for its functional role: from neurochemistry to behaviour. Rev Neurosci 1:157-184
41. 2-like dopamine receptor systems. In: Niznik HB (eds) Dopamine receptors. Marcel Dekker, New York, pp 511-537
42. 2-like' receptors. Prog Neuro-Psychopharmacol Biol Psychiatry 19:811-831
43. 2 agonist effects. Science 236:719-722
44. 1 receptors: efficacy of full (dihydrexidine) vs partial (SKF-38393) agonists in primates vs rodents. Eur J Pharmacol 242:165-172
45. 2 coactivation induces potentiated responses. Brain Res 405:234-246